Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world's largest biotechnology research hub.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/30/16 | $70,000,000 | Series B |
Celgene Corporation DROIA Oncology Ventures Foresite Capital Invus Novartis Stanford University The Column Group | undisclosed |
